遺伝子治療市場：タイプ別、ベクタータイプ別、用途別-2025年～2030年の世界予測

遺伝子治療市場は、2023年に56億7,000万米ドルと評価され、2024年には70億5,000万米ドルに達すると予測され、CAGR 27.15％で成長し、2030年には304億8,000万米ドルに達すると予測されています。

遺伝子治療は、遺伝物質を改変することで病気の治療や予防を目指す革新的な医療アプローチであり、遺伝性疾患、特定のがん、ウイルス感染症に対処する上で計り知れない可能性を秘めています。その必要性は、根本的な遺伝的原因に対処できない従来の治療法の限界から生じています。希少遺伝性疾患の治療、がん治療、血友病治療などに応用され、患者の転帰を著しく向上させる。最終用途としては、主に臨床研究、病院、専門クリニックが挙げられます。

遺伝子治療市場は、遺伝子工学の進歩と研究開発投資の増加により、力強い成長を遂げています。主な成長要因としては、規制当局の支援、遺伝性疾患の有病率の増加、CRISPRのような技術革新などが挙げられます。さらに、新規治療薬のパイプラインの増加や市場参入企業間の戦略的提携は、事業拡大の潜在的機会となります。企業は、アンメットニーズと政府のインセンティブを活用するため、小児適応と新興市場に注力すべきです。しかし、高コスト、倫理的懸念、規制上のハードル、製造の複雑さなどの制約があり、これらは拡張性に課題をもたらし、市場参入を遅らせています。さらに、長期的な安全性と有効性については、引き続き精査が必要です。

革新的な探求は、精度と効率を高めるデリバリーベクターの改良、個別化医療アプローチの開発、遺伝子編集の精度と結果予測のためのAIの活用といった分野に集約されます。市場は急速な進歩を遂げているが、世界の規制や価格設定の課題がさまざまであるため、断片化されたままです。遺伝子技術を改良し、治療範囲を拡大するための共同研究に投資することで、企業は成功することができます。厳密な臨床試験とパートナーシップの必要性は、粘り強さと戦略的先見性を要求する状況を描いています。全体として、既存の課題を克服することに焦点を当てれば、企業はイノベーションを起こし、コストを最適化し、遺伝子治療ソリューションのアクセシビリティを世界的に向上させる機会を得ることができます。

市場力学：急速に進化する遺伝子治療市場の主要な市場インサイトを公開

遺伝子治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の流行と治療センター数の増加
  • 政府の支援と遺伝子治療の治療に対する倫理的受容
• 市場抑制要因
  • 遺伝子治療に伴う高コスト
• 市場機会
  • 希少疾患の研究開発の進行と遺伝子治療の進歩
  • 革新的な支払いモデルと有利な規制当局の承認
• 市場の課題
  • 新しい遺伝子治療に関する潜在的な有害効果と道徳的懸念

ポーターの5つの力遺伝子治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、遺伝子治療市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：遺伝子治療市場における外部からの影響の把握

外部マクロ環境要因は、遺伝子治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析遺伝子治療市場における競合情勢の把握

遺伝子治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス遺伝子治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、遺伝子治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の罹患率の増加と治療センター数の急増
    • 治療に対する政府の支援と遺伝子治療の倫理的受容
  • 抑制要因
    • 遺伝子治療に伴う高額な費用
  • 機会
    • 希少疾患に関する継続的な研究開発と遺伝子治療の進歩
    • 革新的な支払いモデルと有利な規制承認
  • 課題
    • 新しい遺伝子治療に関する潜在的な有害影響と道徳的懸念
• 市場セグメンテーション分析
  • タイプ：がんの有病率がん治療の遺伝子治療
  • ベクタータイプ：ウイルスベクターの大幅な利用により、細胞への遺伝子送達の効率が向上
  • 用途：心血管疾患の治療における革新的なアプローチとしての遺伝子治療の採用の可能性
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 遺伝子治療市場：タイプ別

• 抗原遺伝子治療
• がん遺伝子治療
• サイトカイン遺伝子治療
• 自殺遺伝子治療
• 腫瘍抑制因子遺伝子治療

第7章 遺伝子治療市場：ベクタータイプ別

• 非ウイルスベクター
• ウイルスベクター

第8章 遺伝子治療市場：用途別

• 心血管疾患
• 遺伝性疾患
• 感染症
• 神経疾患
• 腫瘍性疾患

第9章 南北アメリカの遺伝子治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の遺伝子治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの遺伝子治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • チャールズリバー、LVVベースの遺伝子治療製造を促進するLentivationプラットフォームを発表
  • ローラス、インドで遺伝子治療アセットを発売
  • ブルーバードバイオ、鎌状赤血球症の申請が近づく中、遺伝子治療の立ち上げ準備を進める

企業一覧

• Cellectis, Inc.
• Novartis AG
• Biogen Inc.
• AnGes, Inc.
• Orchard Therapeutics PLC
• Poseida Therapeutics, Inc.
• Astellas Gene Therapies
• Sarepta Therapeutics, Inc.
• Uniqure N.V.
• Applied Genetic Technologies Corporation
• Mustang Bio
• Abeona Therapeutics Inc.
• Adaptimmune Therapeutics PLC
• Shenzhen SiBiono GeneTech Co. Ltd.
• Spark Therapeutics, Inc.
• Ionis Pharmaceuticals, Inc.
• Amgen Inc.
• Sangamo Therapeutics, Inc.
• AGC Biologics.
• Merck & Co., Inc.
• American Gene Technologies Inc.
• Editas Medicine, Inc.
• Bluebird Bio, Inc.
• Alnylam Pharmaceuticals, Inc.
• Human Stem Cells Institute

LIST OF FIGURES

• FIGURE 1. GENE THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. GENE THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GENE THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GENE THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY ANTIGEN GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY CANCER GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY CYTOKINE GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY SUICIDE GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY TUMOR SUPPRESSOR GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CHINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CHINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ITALY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ITALY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. POLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 118. POLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. QATAR GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 121. QATAR GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 150. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Gene Therapy Market was valued at USD 5.67 billion in 2023, expected to reach USD 7.05 billion in 2024, and is projected to grow at a CAGR of 27.15%, to USD 30.48 billion by 2030.

Gene therapy, a transformative medical approach aiming to treat or prevent diseases by modifying genetic material, holds immense potential in addressing inherited disorders, certain cancers, and viral infections. Its necessity arises from the limitation of traditional therapies unable to address root genetic causes. Applications include the treatment of rare genetic disorders, cancer therapy, and hemophilia, significantly enhancing patient outcomes. In terms of end-use, gene therapy primarily finds application in clinical research, hospitals, and specialty clinics.

The gene therapy market is experiencing robust growth, driven by advancements in genetic engineering and increased investment in research and development. Key growth factors include regulatory support, an increase in the prevalence of genetic diseases, and technological innovations like CRISPR. Additionally, the growing pipeline of novel therapies and strategic collaborations among market players present potential opportunities for expansion. Companies should focus on pediatric indications and emerging markets to leverage unmet needs and governmental incentives. However, limitations include high costs, ethical concerns, regulatory hurdles, and manufacturing complexities, which challenge scalability and delay market entry. Moreover, long-term safety and efficacy continue to be under scrutiny.

Innovative exploration can be concentrated in areas such as improving delivery vectors for better precision and efficiency, developing personalized medicine approaches, and utilizing AI for gene-editing precision and forecasting outcomes. The market features rapid advancements but remains fragmented due to varying global regulations and price-setting challenges. Businesses can thrive by investing in collaborative research to refine genetic technologies and expand therapeutic scopes. The necessity for rigorous clinical trials and partnerships depicts a landscape demanding persistence and strategic foresight. All in all, with a focus on overcoming existing challenges, businesses have the opportunity to innovate, optimize costs, and improve the accessibility of gene therapy solutions globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gene Therapy Market

The Gene Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Prevalence of Chronic Diseases and Upsurge in Number of Gene Therapy Treatment Centers
  • Government Support and Ethical Acceptance of Gene Therapy For Treatments
• Market Restraints
  • High Costs Associated with Gene Therapies
• Market Opportunities
  • Ongoing Research & Development in Orphan Diseases and Advancements in Gene Therapy
  • Innovative Payment Models and Favorable Regulatory Approvals
• Market Challenges
  • Potential Harmful Effects and Moral Concerns Regarding New Gene Therapy

Porter's Five Forces: A Strategic Tool for Navigating the Gene Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gene Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gene Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gene Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gene Therapy Market

A detailed market share analysis in the Gene Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gene Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gene Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Cellectis, Inc., Novartis AG, Biogen Inc., AnGes, Inc., Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Astellas Gene Therapies, Sarepta Therapeutics, Inc., Uniqure N.V., Applied Genetic Technologies Corporation, Mustang Bio, Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, Shenzhen SiBiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Amgen Inc., Sangamo Therapeutics, Inc., AGC Biologics., Merck & Co., Inc., American Gene Technologies Inc., Editas Medicine, Inc., Bluebird Bio, Inc., Alnylam Pharmaceuticals, Inc., and Human Stem Cells Institute.

Market Segmentation & Coverage

This research report categorizes the Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy, Suicide Gene Therapy, and Tumor Suppressor Gene Therapy.
• Based on Vector Type, market is studied across Non-viral Vectors and Viral Vectors.
• Based on Application, market is studied across Cardiovascular Diseases, Genetic Diseases, Infectious Diseases, Neurological Diseases, and Oncological Disorders.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Prevalence of Chronic Diseases and Upsurge in Number of Gene Therapy Treatment Centers
    • 5.1.1.2. Government Support and Ethical Acceptance of Gene Therapy For Treatments
  • 5.1.2. Restraints
    • 5.1.2.1. High Costs Associated with Gene Therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing Research & Development in Orphan Diseases and Advancements in Gene Therapy
    • 5.1.3.2. Innovative Payment Models and Favorable Regulatory Approvals
  • 5.1.4. Challenges
    • 5.1.4.1. Potential Harmful Effects and Moral Concerns Regarding New Gene Therapy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Prevalence of cancer gene therapy for cancer treatment
  • 5.2.2. Vector Type: Significant utilization of viral vector providing higher efficiency in delivering genes into cells
  • 5.2.3. Application: Potential adoption of gene therapy as a revolutionary approach to treating cardiovascular diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Gene Therapy Market, by Type

• 6.1. Introduction
• 6.2. Antigen Gene Therapy
• 6.3. Cancer Gene Therapy
• 6.4. Cytokine Gene Therapy
• 6.5. Suicide Gene Therapy
• 6.6. Tumor Suppressor Gene Therapy

7. Gene Therapy Market, by Vector Type

• 7.1. Introduction
• 7.2. Non-viral Vectors
• 7.3. Viral Vectors

8. Gene Therapy Market, by Application

• 8.1. Introduction
• 8.2. Cardiovascular Diseases
• 8.3. Genetic Diseases
• 8.4. Infectious Diseases
• 8.5. Neurological Diseases
• 8.6. Oncological Disorders

9. Americas Gene Therapy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Gene Therapy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Gene Therapy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
  • 12.3.2. Laurus to launch Gene Therapy Assets in India
  • 12.3.3. Bluebird bio Lays Gene Therapy Launch Groundwork As Sickle Cell Application Nears

Companies Mentioned

• 1. Cellectis, Inc.
• 2. Novartis AG
• 3. Biogen Inc.
• 4. AnGes, Inc.
• 5. Orchard Therapeutics PLC
• 6. Poseida Therapeutics, Inc.
• 7. Astellas Gene Therapies
• 8. Sarepta Therapeutics, Inc.
• 9. Uniqure N.V.
• 10. Applied Genetic Technologies Corporation
• 11. Mustang Bio
• 12. Abeona Therapeutics Inc.
• 13. Adaptimmune Therapeutics PLC
• 14. Shenzhen SiBiono GeneTech Co. Ltd.
• 15. Spark Therapeutics, Inc.
• 16. Ionis Pharmaceuticals, Inc.
• 17. Amgen Inc.
• 18. Sangamo Therapeutics, Inc.
• 19. AGC Biologics.
• 20. Merck & Co., Inc.
• 21. American Gene Technologies Inc.
• 22. Editas Medicine, Inc.
• 23. Bluebird Bio, Inc.
• 24. Alnylam Pharmaceuticals, Inc.
• 25. Human Stem Cells Institute